Ace-ylation in the hole

Mutant-selective KRAS-targeting drugs hold great promise for the treatment of some of the most aggressive forms of cancer. Building on the breakthrough success of KRAS-G12C inhibitors, researchers have now found a way to target another mutant KRAS with serine-modifying covalent inhibitors.

Saved in:
Bibliographic Details
Published inNature chemical biology Vol. 18; no. 11; pp. 1166 - 1167
Main Authors J Niphakis, Micah, F Cravatt, Benjamin
Format Journal Article
LanguageEnglish
Published Cambridge Nature Publishing Group 01.11.2022
Subjects
Biology
Cancer
Cell growth
Chemistry
Chemists
Drug delivery
Drugs
Inhibitors
Ligands
Mutants
Mutation
Proteins
Success
Tumorigenesis
Online AccessGet full text

Cover

More Information
Summary:Mutant-selective KRAS-targeting drugs hold great promise for the treatment of some of the most aggressive forms of cancer. Building on the breakthrough success of KRAS-G12C inhibitors, researchers have now found a way to target another mutant KRAS with serine-modifying covalent inhibitors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1552-4450
1552-4469
DOI:10.1038/s41589-022-01083-7